Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 2/3 2Phase 3 1Phase 1 1

Status

Unknown 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 163INDUSTRY 43NETWORK 10OTHER_GOV 4UNKNOWN 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Letrozole × Clear all
NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Fujian Cancer Hospital

Phase 2 Not yet recruiting
200 enrolled
Breast

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms

NCT03497702 2018-04-13

NeoChAI

National Cancer Center, Korea

Phase 2 Unknown
114 enrolled
Breast

Breast Neoplasms

NCT00532272 2011-06-27

Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC

National Cancer Center, Korea

Phase 2 Completed
78 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡